Workflow
深夜突发!300078,涉嫌欺诈发行证券案!公安出手了

Core Viewpoint - Sichuang Medical is under investigation by Hangzhou Public Security Bureau for suspected fraudulent issuance of securities, marking the first time this issue has been publicly acknowledged since its listing in April 2010 [2][4][9]. Group 1: Investigation and Legal Issues - On August 14, Sichuang Medical received a notice from Hangzhou Public Security Bureau requesting evidence related to the investigation of fraudulent securities issuance [9]. - The investigation is currently in the police inquiry stage, and no definitive conclusions have been reached yet [9]. - Sichuang Medical was previously penalized by Zhejiang Securities Regulatory Bureau for fraudulent issuance and information disclosure violations, with investigations concluding on January 8, 2024 [11]. Group 2: Financial Performance and Irregularities - Sichuang Medical reported inflated revenues and profits through fraudulent activities, with a total of 34.93 million yuan in inflated revenue and 33.02 million yuan in inflated profits for 2019, and 60.96 million yuan in inflated revenue and 52.37 million yuan in inflated profits for the first three quarters of 2020 [15]. - The company has been in a continuous loss state, with net profits attributable to shareholders of -878 million yuan in 2022, -874 million yuan in 2023, and -501 million yuan in 2024 [23][24]. Group 3: Fundraising and Investment Issues - Sichuang Medical has conducted capital operations, including a non-public stock issuance in 2019 and a convertible bond issuance in 2021, but failed to fully invest the raised funds in planned projects, with only liquidity support being completed [18][20]. - Specific projects like the Internet + AI medical innovation service project and marketing system expansion project saw minimal investment compared to planned amounts, with only 0.23 million yuan and 0.07 million yuan invested respectively against planned investments of 333 million yuan and 131 million yuan [20][22].